期刊
PATHOLOGY & ONCOLOGY RESEARCH
卷 25, 期 3, 页码 1059-1066出版社
FRONTIERS MEDIA SA
DOI: 10.1007/s12253-018-0464-y
关键词
Pancreatic cancer; Ki67; P53; CA19-9; Prognosis
资金
- Seed grant from the American University of Beirut
We investigated the expression patterns of Ki67 and p53 in metastatic pancreatic adenocarcinomas and analyzed their relationship with disease progression-free survival (PFS) and overall survival (OS) in the overall study population and in patients treated with a gemcitabine-containing chemotherapy versus FOLFIRINOX chemotherapy. Patients with histologically confirmed stage IV adenocarcinoma of the pancreas treated at AUBMC were included after obtaining institutional review board approval (IRB ID: IM.ST.05). The ROC was plotted to identify the threshold Ki-67, p53 and CA19-9 value for disease progression, the identified value was further used in Kaplan Meier curves to compare PFS for both groups (gemcitabine versus FOLFIRINOX). A value of p<0.05 was considered significant in all analyses. On univariate analysis, patients who had a Ki-67>12.5% or a p53>15% had significantly shorter PFS (p=0.034 and p=0.016, respectively). This effect was restricted to Gemcitabine or gemcitabine-combination treated patients. A decrease in CA19-9 levels 6-8weeks after chemotherapy of >58% had significantly longer PFS (p=0.027). On multivariate analysis after controlling for grade, age and P53, Ki-67 remained significant, for every one unit increase in Ki-67 the progression risk increases by 1.017 times. Our study highlights the negative impact of high P53 expression and Ki67 proliferation index on PFS in patients with metastatic pancreatic cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据